P2RY12 and atrial fibrillation: Recent studies have investigated the use of DOACs combined with a P2Y12 inhibitor as compared to warfarin in patients with nonvalvular atrial fibrillation undergoing PCI (PIONEER AF-PCI for rivaroxaban, RE-DUAL PCI for dabigatran, AUGUSTUS for abixaban, ENTRUST-AF PCI for edoxban), and have shown reduced risk of bleeding without increased risk of thrombosis [73].